Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus
UNION CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the release of a new Piccolo® reagent disc panel called BioChemistry Panel Plus. This new reagent disc will be used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer. As a result of this new panel configuration, U.S. healthcare professionals can now conduct on-site chemistry analysis in less than 12 minutes for general inflammation and infection in combination with comprehensive liver and kidney function diagnostics.
The new BioChemistry Panel Plus contains the C-Reactive Protein (CRP) assay that received 510(k) clearance in late January 2010. In addition to CRP, the BioChemistry Panel Plus contains the following test configuration: ALB, ALP, ALT, AMY, AST, BUN, Ca, CRE, GGT, GLU, TP, UA. This configuration encompasses a broad spectrum of internal organ diagnostics including liver, kidney, pancreas and metabolic functions.
The BioChemistry Panel Plus is likely to be useful for practices that are interested in the detection, monitoring and treatment of diseases with inflammation or infection disorders. The new panel may also have broad applications in the European and Asia Pacific markets, where CRP is widely used as a standard test in general health screenings and as part of routine clinical practice.
"The addition of the new BioChemistry Panel Plus is a testament to our commitment to continued innovation in medical diagnostics," said Clint Severson, chairman and chief executive officer of Abaxis, Inc. "We look forward to continuing to raise the bar on diagnostic technologies that allow physicians to better care for their patients, improve the efficiencies of their practices and reduce the overall cost of healthcare, while increasing